Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers
Location: United States, California, San Francisco
Total raised: $25M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2019 | - | $25M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 16.02.2021 | Viracta Therapeutics Announces Notice of Allowance for U.S. ... | SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a pr... | prnewswire... |
| 07.12.2020 | Viracta Therapeutics Announces Presentation of Updated Phase... | SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a pre... | prnewswire... |
| 11.07.2019 | Sunesis Announces Pricing of $25 Million Offering of Securit... | SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (NASDAQ:... | aislingcap... |
| 27.02.2014 | Sunesis Announces Pricing of a $43.0 Million Public Offering... | Total Gross Proceeds of $138.3 Million Assuming the Potential Exercise of All Warrants SOUTH SAN FR... | baycitycap... |
| 01.10.2010 | Sunesis Adds $15.5M | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Sunesis Pharmaceuticals (NASDAQ: S... | xconomy.co... |
| 22.10.2007 | Life sciences briefing: Monday, Oct. 22, 2007 | Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas... | venturebea... |